Compare Amcor PLC (AMCR) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Humana Inc — how do they compare? Amcor PLC trades at $46.58 (market cap $21.92B), while Humana Inc trades at $388 (market cap $44.77B). The key difference: Humana Inc is far larger — about 2× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (5.49%). Which is the better fit depends on your goals.
| AMCR | HUM | |
|---|---|---|
Market Cap | $21.92B | $44.77B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $409.42 |
52-Week Low | $36.69 | $163.67 |
Enterprise Value | $37.03B | $52.12B |
Dividend Yield | 5.49% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.24, up 0.28% today, near the analyst consensus price target of $47.00. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.23, beating estimates, with revenue growth driven by the Berry acquisition. Net income margin stands at 3.06%, while the P/E ratio of 38.07 indicates a premium valuation. Recent news highlights strong Q4 earnings and expansion in China.
The outlook for AMCR is cautiously optimistic, supported by consistent earnings beats and strategic expansions. However, elevated valuation metrics and a high RSI pose near-term risks. Investor sentiment is positive with a 64% analyst buy rating, but margin pressures and integration risks from acquisitions warrant monitoring. The stock presents a balanced opportunity with growth catalysts tempered by valuation concerns.
Humana (HUM) trades at $388.96, up 0.9% with a neutral technical signal. The stock shows strong revenue growth reaching $129.7B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent earnings beat expectations for three consecutive quarters, while analyst consensus targets $409.93. The company maintains solid cash flow generation and recently announced key leadership appointments to strengthen its Medicaid business.
Humana presents a mixed outlook with robust revenue expansion offset by margin pressures. Investment opportunity lies in Medicare Advantage growth and cost reduction initiatives, while risks include competitive pressures and regulatory changes in healthcare. Wall Street maintains cautious optimism with 39% buy ratings amid margin recovery challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
